Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.

Publication ,  Journal Article
Ford, J; Thuro, BA; Thakar, S; Hwu, W-J; Richani, K; Esmaeli, B
Published in: Ophthalmic Plast Reconstr Surg
2017

Programmed cell death 1 (PD-1) inhibitors are members of a new class of drugs known as immune checkpoint inhibitors and have proven efficacy in the treatment of metastatic melanoma. Herein, the authors report the use of nivolumab and pembrolizumab, 2 recently Food and Drug Administration-approved PD-1 inhibitors, in 3 patients: 1 with metastatic conjunctival melanoma and 2 with metastatic cutaneous melanoma and orbital involvement. The patients' metastatic disease responded well to drug treatment. As of this writing, 2 patients have completed therapy and remain disease free at least 1 year after treatment completion; the other patient is still receiving treatment, and his orbital disease is responding. The authors herein describe the use of PD-1 inhibitors as a new alternative in the treatment of metastatic melanoma to the orbit or metastatic ocular adnexal melanomas in these clinical settings.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ophthalmic Plast Reconstr Surg

DOI

EISSN

1537-2677

Publication Date

2017

Volume

33

Issue

4

Start / End Page

e82 / e85

Location

United States

Related Subject Headings

  • Programmed Cell Death 1 Receptor
  • Orbital Neoplasms
  • Ophthalmology & Optometry
  • Nivolumab
  • Melanoma
  • Male
  • Immunotherapy
  • Humans
  • Female
  • Conjunctival Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ford, J., Thuro, B. A., Thakar, S., Hwu, W.-J., Richani, K., & Esmaeli, B. (2017). Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa. Ophthalmic Plast Reconstr Surg, 33(4), e82–e85. https://doi.org/10.1097/IOP.0000000000000790
Ford, Joshua, Bradley A. Thuro, Sudip Thakar, Wen-Jen Hwu, Karina Richani, and Bita Esmaeli. “Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.Ophthalmic Plast Reconstr Surg 33, no. 4 (2017): e82–85. https://doi.org/10.1097/IOP.0000000000000790.
Ford J, Thuro BA, Thakar S, Hwu W-J, Richani K, Esmaeli B. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa. Ophthalmic Plast Reconstr Surg. 2017;33(4):e82–5.
Ford, Joshua, et al. “Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.Ophthalmic Plast Reconstr Surg, vol. 33, no. 4, 2017, pp. e82–85. Pubmed, doi:10.1097/IOP.0000000000000790.
Ford J, Thuro BA, Thakar S, Hwu W-J, Richani K, Esmaeli B. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa. Ophthalmic Plast Reconstr Surg. 2017;33(4):e82–e85.

Published In

Ophthalmic Plast Reconstr Surg

DOI

EISSN

1537-2677

Publication Date

2017

Volume

33

Issue

4

Start / End Page

e82 / e85

Location

United States

Related Subject Headings

  • Programmed Cell Death 1 Receptor
  • Orbital Neoplasms
  • Ophthalmology & Optometry
  • Nivolumab
  • Melanoma
  • Male
  • Immunotherapy
  • Humans
  • Female
  • Conjunctival Neoplasms